Trade ANAB stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
AnaptysBio, Inc. (ANAB) is trading at US$55.20, up 0.25% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$1.71B. Over the past 52 weeks, ANAB has traded between US$20.49 and US$73.30. On Syfe you can trade ANAB with $0 commission and add it to your watchlist.
| Previous close | US$55.06 |
|---|---|
| Market cap | US$1.71B |
| P/E ratio | 38.77 |
| 52-week range | US$20.49 – US$73.30 |
| Volume | 847.12K |
| Exchange | US |
Add to Watchlist
Set Price Alert
AnaptysBio, Inc.
AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The firm’s product pipeline includes Rosnilimab, ANB033, ANB101, Jemperli, and Imsidolimab. It operates through the Biopharma and Royalty Management segments. The Biopharma segment focuses on the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases. The Royalty Management segment manages the financial collaboration for Jemperli with GSK and for imsidolimab with Vanda. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Year: 2017
UBS Adjusts Price Target on AnaptysBio to $76 From $70, Maintains Buy Rating
May 13, 1:58 PM · MT Newswires
-- Earnings Flash (ANAB) AnaptysBio, Inc. Reports Q1 Revenue $25.6M, vs. FactSet Est of $18.9M
May 12, 8:15 PM · MT Newswires
AnaptysBio Appoints Chris Murphy as CFO, Owen Hughes to Board
May 11, 1:51 PM · MT Newswires
GSK's Tesaro Gets Favorable Ruling in AnaptysBio License Dispute
Apr 27, 8:29 AM · MT Newswires
AnaptysBio Gets Favorable Ruling by Delaware Chancery Court in Tesaro's Anticipatory Breach Claim
Apr 24, 8:21 PM · MT Newswires
AnaptysBio, Inc. (ANAB) stock is trading at US$55.20, +0.25% from the previous close of US$55.06.
The market cap for AnaptysBio, Inc. (ANAB) stock is approximately US$1.71B.
The price-to-earnings ratio for AnaptysBio, Inc. (ANAB) is 38.77, based on the latest reported earnings.
The 52-week high for AnaptysBio, Inc. (ANAB) stock is US$73.30.
The 52-week low for AnaptysBio, Inc. (ANAB) stock is US$20.49.
AnaptysBio, Inc. (ANAB) does not currently pay a dividend.
Stay on top of ANAB
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
